Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tolosa, E.
Right arrow Articles by Molinuevo, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tolosa, E.
Right arrow Articles by Molinuevo, J. L.

Neurology, Vol 50, Issue 6 S2-10, Copyright © 1998 by American Academy of Neurology

ARTICLES

History of levodopa and dopamine agonists in Parkinson's disease treatment

E Tolosa, MJ Marti, F Valldeoriola and JL Molinuevo
Parkinson's Disease and Movement Disorder Unit, Neurology Service, University Hospital Clinic, Barcelona, Spain.

Striatal dopamine deficiency in Parkinson's disease (PD), first described in 1960, was a key event that led to the era of levodopa therapy. In 1961, levodopa was first tried in PD patients, but throughout most of the 1960s the results were inconsistent. In 1967, questions about the effectiveness of levodopa in PD were finally set aside when Cotzias and colleagues reported dramatic improvement in PD patients with oral administration of levodopa in increasing amounts over long periods. The major side effects of levodopa administration, i.e., dyskinesias and motor fluctuations, also became apparent at this time. In the early 1970s, the advantages of adding a dopa decarboxylase inhibitor to treatment were discovered--reducing side effects and gaining better symptom control--and the first levodopa combination, carbidopa/levodopa, became commercially available in 1975. Since then, PD researchers have attempted to overcome complications with such techniques as continuous levodopa infusion and, most recently, long- acting levodopa combinations. A dopamine agonist, apomorphine, was used in 1970 as a means to overcome side effects and loss of levodopa efficacy. However, side effects and difficulty of administration limited its use. Dopamine agonists began to find a place in routine treatment of PD after the discovery of bromocriptine's benefits in PD in 1974. Since then, new approaches have been tried, such as dopamine agonist monotherapy and early therapy in combination with levodopa. The development of new dopamine agonists has led to characterization of dopamine receptor subtypes and agonists targeted to stimulation of specific receptors.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M.-F. Wu, J. John, N. Maidment, H. A. Lam, and J. M. Siegel
Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2002; 283(5): R1079 - R1086.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
S. Fraga, M. P. Serrao, and P. Soares-da-Silva
L-Type Amino Acid Transporters in Two Intestinal Epithelial Cell Lines Function as Exchangers with Neutral Amino Acids
J. Nutr., April 1, 2002; 132(4): 733 - 738.
[Abstract] [Full Text] [PDF]

Home page
 Genome ResHome page
M. Hungs, J. Fan, L. Lin, X. Lin, R. A. Maki, and E. Mignot
Identification and Functional Analysis of Mutations in the Hypocretin (Orexin) Genes of Narcoleptic Canines
Genome Res., April 1, 2001; 11(4): 531 - 539.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by AAN Enterprises, Inc.